GTI 2040

GTI-2040, a 20-mer phosphorothioate oligonucleotide, was designed to hybridize to the mRNA sequence of human ribonucleotide reductase R2. GTI-2040 has been shown to inhibit human cancer cell proliferation by downregulation of R2 expression in vitro and to significantly inhibit tumor growth in xenograft models of human cancer in mice.

Product Specifications

CAS Number

[236391-66-5]

UNSPSC

12352208

Target

DNA/RNA Synthesis

Type

Oligonucleotides

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/gti-2040.html

Solubility

10 mM in H2O

Smiles

[GTI2040]

References & Citations

[1]Vassilakos A, Lee Y, Viau S, et al. GTI-2040 displays cooperative anti-tumor activity when combined with interferon alpha against human renal carcinoma xenografts. Int J Oncol. 2009;34 (1) :33-42.|[2]Ferdinandi ES, Vassilakos A, Lee Y, et al. Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2. Cancer Chemother Pharmacol. 2011;68 (1) :193-205. doi:10.1007/s00280-010-1473-z